Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

BACKGROUND: The prostate tumor microenvironment (TME) is immunosuppressive, with few effector T cells and enrichment of inhibitory immune populations, leading to limited responses to treatments such as immune checkpoint therapies (ICTs). The immune composition of the prostate TME differs across soft...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqui, Bilal A, Chapin, Brian F, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S, Gu, Ai-Di, Espejo, Alexsandra B, Kinder, Michelle, Pettaway, Curtis A, Ward, John F, Tidwell, Rebecca S S, Troncoso, Patricia, Corn, Paul G, Logothetis, Christopher J, Knoblauch, Roland, Hutnick, Natalie, Gottardis, Marco, Drake, Charles G, Sharma, Padmanee, Subudhi, Sumit K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040066/
https://www.ncbi.nlm.nih.gov/pubmed/36948506
http://dx.doi.org/10.1136/jitc-2022-006262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040066/
https://www.ncbi.nlm.nih.gov/pubmed/36948506
http://dx.doi.org/10.1136/jitc-2022-006262

Ejemplares similares